$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000156459017002409 Filed on February 24, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$3.534B	$3.526B	$3.435B
YoY Change	6.18%	8.42%	8.26%
Cost Of Revenue	$2.515B	$2.501B	$2.446B
YoY Change	6.28%	7.5%	8.88%
Gross Profit	$1.019B	$1.025B	$988.5M
YoY Change	5.92%	10.74%	6.75%
Gross Profit Margin	28.82%	29.06%	28.78%
Selling, General & Admin	$407.6M	$356.0M	$354.2M
YoY Change	12.97%	8.94%	17.36%
% of Gross Profit	40.02%	34.74%	35.83%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$163.3M	$162.1M	$158.8M
YoY Change	6.32%	8.65%	8.84%
% of Gross Profit	16.03%	15.82%	16.06%
Operating Expenses	$571.0M	$518.1M	$513.0M
YoY Change	11.11%	8.84%	14.56%
Operating Profit	$244.9M	$509.4M	$480.5M
YoY Change	-45.82%	16.42%	-0.77%
Interest Expense	-$95.70M	-$100.7M	-$147.3M
YoY Change	2.46%	6.34%	-25.46%
% of Operating Profit	-39.07%	-19.77%	-30.65%
Other Income/Expense, Net	$4.600M	$2.500M	$2.311M
YoY Change	2200.0%	-300.64%	36.5%
Pretax Income	$146.3M	$408.4M	$330.5M
YoY Change	-58.71%	21.39%	17.08%
Income Tax	$111.8M	$147.1M	$122.8M
% Of Pretax Income	76.41%	36.02%	37.14%
Net Earnings	-$6.000M	$215.9M	$170.5M
YoY Change	-102.88%	17.24%	15.43%
Net Earnings / Revenue	-0.17%	6.12%	4.96%
Basic Earnings Per Share	-$0.03	$1.02	$0.80
Diluted Earnings Per Share	-$0.03	$1.00	$0.78
COMMON SHARES
Basic Shares Outstanding			213.0M
Diluted Shares Outstanding			217.6M

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.742B	$2.000B	$1.906B
YoY Change	58.23%	19.86%	28.32%
Cash & Equivalents	$1.245B	$1.047B	$933.7M
Short-Term Investments	$497.2M	$953.0M	$971.8M
Other Short-Term Assets	$190.3M	$429.0M	$189.5M
YoY Change	1.86%	149.05%	15.15%
Inventory	$185.6M	$173.0M	$159.4M
Prepaid Expenses	$105.2M
Receivables	$1.724B	$1.700B	$1.667B
Other Receivables	$435.9M	$466.0M	$456.5M
Total Short-Term Assets	$4.503B	$4.738B	$4.781B
YoY Change	23.85%	13.39%	14.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.789B	$2.622B	$2.565B
YoY Change	12.95%	11.14%	11.97%
Goodwill	$5.896B	$9.488B
YoY Change	-37.38%	1.53%
Intangibles	$1.687B
YoY Change	-9.52%
Long-Term Investments	$167.0M	$158.0M	$160.0M
YoY Change	7.74%	2.6%	23.08%
Other Assets	$73.56M	$62.39M	$122.0M
YoY Change	-4.47%	-7.34%	84.55%
Total Long-Term Assets	$14.01B	$14.16B	$14.17B
YoY Change	0.22%	1.68%	2.92%
TOTAL ASSETS
Total Short-Term Assets	$4.503B	$4.738B	$4.781B
Total Long-Term Assets	$14.01B	$14.16B	$14.17B
Total Assets	$18.51B	$18.89B	$18.95B
YoY Change	5.09%	4.38%	5.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$514.0M	$487.9M	$490.0M
YoY Change	15.38%	10.35%	20.76%
Accrued Expenses	$895.0M	$836.0M	$679.0M
YoY Change	8.62%	9.71%	8.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$129.0M	$115.0M	$109.0M
YoY Change	7.5%	-5.37%	-6.9%
Total Short-Term Liabilities	$2.399B	$2.411B	$2.334B
YoY Change	14.87%	-7.2%	-10.51%
LONG-TERM LIABILITIES
Long-Term Debt	$9.001B	$9.082B	$9.101B
YoY Change	8.46%	8.36%	8.46%
Other Long-Term Liabilities	$439.2M	$406.0M	$400.0M
YoY Change	12.68%	10.19%	3.62%
Total Long-Term Liabilities	$439.2M	$406.0M	$9.501B
YoY Change	12.68%	10.19%	2361.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.399B	$2.411B	$2.334B
Total Long-Term Liabilities	$439.2M	$406.0M	$9.501B
Total Liabilities	$12.57B	$12.81B	$13.80B
YoY Change	9.97%	5.04%	13.04%
SHAREHOLDERS EQUITY
Retained Earnings	$4.357B	$4.363B
YoY Change	6.6%	12.47%
Common Stock	$1.119B	$1.107B
YoY Change	0.91%	514578.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$544.8M	$424.7M
YoY Change
Treasury Stock Shares	$7.366M	$5.623M
Shareholders Equity	$4.871B	$4.990B	$5.147B
YoY Change
Total Liabilities & Shareholders Equity	$18.51B	$18.89B	$18.95B
YoY Change	5.09%	4.38%	5.7%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	-$6.000M	$215.9M	$170.5M
YoY Change	-102.88%	17.24%	15.43%
Depreciation, Depletion And Amortization	$163.3M	$162.1M	$158.8M
YoY Change	6.32%	8.65%	8.84%
Cash From Operating Activities	$436.7M	$679.0M	$31.40M
YoY Change	-723.86%	-19.92%	-88.03%
INVESTING ACTIVITIES
Capital Expenditures	-$245.8M	$171.3M	$169.5M
YoY Change	24.27%	3.9%	11.46%
Acquisitions
YoY Change
Other Investing Activities	$514.4M	-$31.70M	-$525.6M
YoY Change	-306.84%	-85.81%	452.68%
Cash From Investing Activities	$268.6M	-$203.1M	-$695.0M
YoY Change	-160.16%	-47.7%	181.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-252.9M	-361.2M	586.0M
YoY Change	449.78%	1.57%	96.18%
NET CHANGE
Cash From Operating Activities	436.7M	679.0M	31.40M
Cash From Investing Activities	268.6M	-203.1M	-695.0M
Cash From Financing Activities	-252.9M	-361.2M	586.0M
Net Change In Cash	452.4M	114.7M	-77.60M
YoY Change	-180.43%	10.29%	-124.71%
FREE CASH FLOW
Cash From Operating Activities	$436.7M	$679.0M	$31.40M
Capital Expenditures	-$245.8M	$171.3M	$169.5M
Free Cash Flow	$682.5M	$507.7M	-$138.1M
YoY Change	434.04%	-25.67%	-225.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	194600000
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Trading Symbol TradingSymbol	DVA
CY2016	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC.
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2016	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	296408000
CY2015	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	210234000
CY2016	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	404165000
CY2015	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	495000000
CY2014	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	17000000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	1815141000
CY2014	us-gaap	Interest And Debt Expense InterestAndDebtExpense	410294000
CY2014	dva	Debt Refinancing Charge DebtRefinancingCharge	97548000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2374000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1309673000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	446343000
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000
CY2015	us-gaap	Profit Loss ProfitLoss	427410000
CY2014	us-gaap	Profit Loss ProfitLoss	863330000
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	153208000
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	157678000
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	140216000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	269732000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	723114000
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.36
CY2014	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	140216000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2788740000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3175367000
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.41
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18741257000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	850057000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18514875000
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1527767000
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.29
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.33
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201641173
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	211867714
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	212301827
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204904656
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216251807
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216927681
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-3670000
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-12241000
CY2014	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-10059000
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-2566000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3111000
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-10608000
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1427000
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1413000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	238000
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	423000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	377000
CY2014	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	207000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-39614000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-23889000
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-22952000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-10087000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29627000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-34809000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22372000
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1003455000
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	392601000
CY2014	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	840958000
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	153398000
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	157678000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	234923000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	700742000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	913187000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1499116000
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	310198000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	408084000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1917302000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1724228000
CY2016Q4	us-gaap	Inventory Net InventoryNet	164858000
CY2015Q4	us-gaap	Inventory Net InventoryNet	185575000
CY2016Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	453483000
CY2015Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	435885000
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	210604000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	190322000
CY2016Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	10596000
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	60070000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3980228000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	4503280000
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5084172000
CY2015Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	864066000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1687326000
CY2016Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	502389000
CY2015Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	78368000
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	103679000
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	89122000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44510000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73560000
CY2016Q4	us-gaap	Goodwill Goodwill	9407317000
CY2015Q4	us-gaap	Goodwill Goodwill	9294479000
CY2016Q4	us-gaap	Assets Assets	18741257000
CY2015Q4	us-gaap	Assets Assets	18514875000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	522415000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	513950000
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	856847000
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	682123000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	815761000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	741926000
CY2016Q4	dva	Medical Expense Payable MedicalExpensePayable	336381000
CY2015Q4	dva	Medical Expense Payable MedicalExpensePayable	332102000
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	165041000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	129037000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2696445000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2399138000
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8947327000
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9001308000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	465358000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	439229000
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	809128000
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	726962000
CY2016Q4	us-gaap	Liabilities Liabilities	12918258000
CY2015Q4	us-gaap	Liabilities Liabilities	12566637000
CY2016Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	973258000
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	195000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	217000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1027182000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1118326000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3710313000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4356835000
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	544772000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-89643000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-59826000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4648047000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	4870780000
CY2016Q4	us-gaap	Minority Interest MinorityInterest	201694000
CY2015Q4	us-gaap	Minority Interest MinorityInterest	213392000
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4849741000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	252056000
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	54950000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	264144000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	194554491
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217120346
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	194554491
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	209754247
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	7366099
CY2016	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	720252000
CY2015	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	638024000
CY2014	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	590935000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	38338000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	56664000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	56743000
CY2016	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	28397000
CY2015	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	45749000
CY2014	dva	Employee Service Stock Based Compensation Tax Benefit From Compensation Expense EmployeeServiceStockBasedCompensationTaxBenefitFromCompensationExpense	59119000
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	13251000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	28157000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	45271000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52010000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	61744000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	210955000
CY2016	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-17766000
CY2015	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-9293000
CY2014	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-10125000
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7338000
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-44691000
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-39274000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	152240000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	202867000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	40676000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22920000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	48313000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	46398000
CY2016	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	54038000
CY2015	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-32761000
CY2014	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	61674000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-35893000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3723000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2916000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11897000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30998000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2956000
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	68272000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	97261000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	24175000
CY2016	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	176494000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-60475000
CY2015	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	113470000
CY2015	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	17911000
CY2014	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	83590000
CY2015	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-493775000
CY2014	dva	Increase Decrease In Loss Contingency Payments IncreaseDecreaseInLossContingencyPayments	-410356000
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	62230000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	30517000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	33354000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1583000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1963444000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1557200000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1459407000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829095000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	707998000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	641330000
CY2016	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	563856000
CY2015	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	96469000
CY2014	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	272094000
CY2016	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	64725000
CY2015	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	19715000
CY2014	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	8791000
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13539000
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8783000
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8440000
CY2016	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1133192000
CY2015	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1709883000
CY2014	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	472628000
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	18963000
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2058000
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2475000
CY2016	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1240502000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1637358000
CY2014	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	141072000
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1018000
CY2016	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	27096000
CY2014	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	35382000
CY2016	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	40920000
CY2015	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	129000
CY2014	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	825000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1201668000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-881784000
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	51991490000
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	13251000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26155000
CY2014	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	149339000
CY2014	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	64655000
CY2014	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3777000
CY2016	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	21512000
CY2015	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	66382000
CY2014	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	17876000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1351981000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-138970000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-164979000
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	4276000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2571000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2293000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-585929000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	533875000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18992000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	965241000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	946249000
CY2016	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Contingencies </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in a highly regulated industry and is a party to various lawsuits, claims, governmental investigations and audits (including investigations resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. While these accruals reflect the Company’s best estimate of the probable loss for those matters as the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which may be exacerbated by various factors, including that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inquiries by the Federal Government and Certain Related Civil Proceedings </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vainer Private Civil Suit</font>: As previously disclosed, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act (FCA). The relators also alleged that the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of $450,000 and attorney fees and other costs of $45,000 which was paid in 2015. </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2011 U.S. Attorney Medicaid Investigation</font>: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company’s understanding that this inquiry is civil in nature. The Company understands further that certain other providers that operate dialysis clinics in New York may have received a similar request for documents. The Company cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government. In March 2016, the Company finalized and executed settlement agreements with the State of New York and the U.S. Department of Justice (DOJ), including a settlement payment of an immaterial amount.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Swoben Private Civil Suit</font>: In April 2013, HealthCare Partners (HCP), now known as the Company’s DaVita Medical Group (DMG) subsidiary, was one of several defendants served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), an HMO. On July 13, 2009, pursuant to the <font style="font-style:italic;">qui tam</font> provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed his initial <font style="font-style:italic;">qui tam</font> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In 2009 and 2010, the relator twice amended his complaint and added additional defendants, and in November 2011, he filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, and added additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as HCC and RAF scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The DOJ reviewed these allegations and in January 2013 declined to intervene in the case. HCP and the other defendants filed motions to dismiss the Third Amended Complaint, and the court dismissed with prejudice the claims and judgment was entered in September 2013. Upon the plaintiff’s appeal, a panel of the Ninth Circuit overturned the trial court’s ruling and vacated the dismissal of the case. The Company, with certain defendants, petitioned the Ninth Circuit for a rehearing, but in December 2016, the Ninth Circuit rejected the petition and determined the relator should be given an opportunity to amend the complaint, and remanded the case back to district court.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Attorney Transportation Investigation</font>: In February 2015, the Company announced that it received six administrative subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena sought the medical records of a single patient of each respective dialysis center. In February 2016, the Company received four additional subpoenas for four additional dialysis centers in southern California. The subpoenas were similarly limited in scope to the subpoenas received in 2015. On February 8, 2017, the Company was served with a qui tam complaint in the U.S. District Court for the Central District of California. The Company has been advised by an attorney with the United States Attorney’s Office for the Central District of California that the qui tam is related to the investigation concerning the medical necessity of patient transportation, which was the basis for the subpoenas. The relator alleges that an ambulance company submitted false claims for patient transportation. Although the Company does not provide transportation nor does it bill for the transport of its dialysis patients, the relator alleges that two of its purported clinical staff caused the submission of a small number of those claims through improper certifications of medical necessity. The Company is investigating these allegations and intends to defend accordingly. The DOJ has declined to intervene.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Office of Inspector General (OIG) Medicare Advantage Civil Investigation</font>: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of DMG, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the DOJ in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers’ risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA’s communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government’s investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company’s and its subsidiaries’ (including DMG’s and its subsidiary JSA’s) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested includes information relating to patient diagnosis coding practices for a number of conditions, including potentially improper historical DMG coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012 acquisition of DMG, and the Company notified CMS in April 2015 of the coding practice and potential overpayments. In that regard, the Company has identified certain additional coding practices which may have been problematic and is in discussions with the DOJ about the scope and nature of a review of claims relating to those practices. The Company is cooperating with the government and is producing the requested information. In addition, the Company is continuing to review other DMG coding practices to determine whether there were any improper coding issues. In connection with the DMG merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company has submitted an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred relating to these matters and intends to pursue recovery from the escrow. However, the Company can make no assurances that the indemnification and escrow will cover the full amount of the Company’s potential losses related to these matters. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2015 U.S. Department of Justice Vascular Access Investigation and Related </font><font style="font-style:italic;text-decoration:underline;">Qui Tam</font><font style="text-decoration:underline;"> Litigation</font>: In November 2015, the Company announced that RMS Lifeline, Inc., a wholly-owned subsidiary of the Company that operates under the name Lifeline Vascular Access (Lifeline), received a Civil Investigative Demand (CID) from the DOJ. The CID relates to two vascular access centers in Florida that are part of Lifeline’s vascular access business. The CID covers the period from January 1, 2008 through the present. The Company acquired these two centers in December 2012. Based on the language of the CID, the DOJ appeared to be looking at whether angiograms performed at the two centers were medically unnecessary and therefore whether related claims filed with federal healthcare programs possibly violated the FCA. Lifeline does not perform dialysis services but instead provides <font style="Background-color:#FFFFFF;">vascular access management services for dialysis patients</font>. The Company cooperated with the government and produced the requested information. The DOJ investigation was initiated pursuant to a complaint brought under the <font style="font-style:italic;">qui tam</font> provisions of the FCA (the Complaint). The Complaint was originally filed under seal in August 2014 in the U.S. District Court, Middle District of Florida, United States ex. rel James Spafford v. DaVita HealthCare Partners, Inc., et al., Case Number 6:14-cv-1251-Orl-41DAB, naming several doctors along with the Company as defendants. In December 2015, a First Amended Complaint was filed under seal. In May 2016, the First Amended Complaint was unsealed. The First Amended Complaint alleges violations of the FCA due to the submission of claims to the government for allegedly medically unnecessary angiograms and angiography procedures at the two vascular access centers as well as employment-related claims. The Complaint covers alleged conduct dating from July 2008, prior to the Company’s acquisition of the centers, to the present. The DOJ declined to intervene. In the third quarter of 2016 the Company recorded an accrual of a non-material amount for potential damages and liabilities. In January 2017, the Company finalized and executed a settlement agreement with the relator and the government for an immaterial amount.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2016 U.S. Attorney Prescription Drug Investigation</font>: In early February 2016, the Company announced that its pharmacy services’ wholly-owned subsidiary, DaVita Rx, received a CID from the U.S. Attorney’s Office for the Northern District of Texas. It appears the government is conducting an FCA investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as into the Company’s relationship with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In the spring of 2015, the Company initiated an internal compliance review of DaVita Rx during which it identified potential billing and operational issues. The Company notified the government in September 2015 that it was conducting this review of DaVita Rx and began providing regular updates of its review. As of December 31, 2016, the Company recorded estimated accruals totaling $38,330 for potential damages and liabilities associated with write-offs and discounts of patient co-payment obligations, and credits to payors for returns of prescriptions drugs, related to DaVita Rx that were identified during the course of this internal compliance review. Upon completion of its review, the Company filed a self-disclosure with the OIG in early February 2016 and has been working to address and update the practices it identified in the self-disclosure, some of which overlap with information requested by the U.S. Attorney’s Office. The Company may accrue additional reserves for refunds and related damages and potential liabilities arising out of this review. The Company does not know if the U.S. Attorney’s Office, which is part of the DOJ, knew when it served the CID on the Company that it was already in the process of developing a self-disclosure to the OIG. The OIG informed the Company in February 2016 that its submission was not accepted. They indicated that the OIG is not expressing an opinion regarding the conduct disclosed or the Company’s legal positions. The Company is cooperating with the government and is producing the requested information<font style="color:#000000;">.</font></p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Solari Post-Acquisition Matter</font>:<font style="font-style:italic;"> </font>In 2016, HCP Nevada disclosed to the <font style="color:#000000;">OIG for the Department of Health and Human Services (HHS) that </font>proper procedures for clinical and eligibility determinations may not have been followed by Las Vegas Solari Hospice (Solari), which was acquired in March 2013 and sold in September 2016 by HCP Nevada. In June 2016, the Company was notified by the OIG that the disclosure submission had been accepted into the OIG’s Self Disclosure Protocol. The Company recorded an estimated accrual of $<font style="color:#000000;">16,000 </font>for potential damages and liabilities associated with this matter. HCP Nevada had previously made a disclosure and repayment of overpayments to National Government Services (NGS), the Medicare Administrative Contractor for HCP Nevada, for claims submitted by Solari to the federal government prior to DMG’s acquisition of Solari and claims made to the government post-acquisition for which the sellers had certain responsibilities pursuant to a management services agreement. The Company may accrue additional reserves for potential damages and liabilities related to this matter. The Company is cooperating with the government in this matter.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">2017 U.S. Attorney American Kidney Fund Investigation</font>. On January 4, 2017, the Company was served with an administrative subpoena for records by the United States Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal health care offenses. The subpoena covers the period from January 1, 2007 through the present, and seeks documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Company intends to cooperate with the government in this investigation.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. In addition to the inquiries and proceedings specifically identified above, the Company is frequently subject to other inquiries by state or federal government agencies and/or private civil qui tam complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, possible criminal penalties, any of which could have a material adverse effect on the Company. </p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shareholder Claims </p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Peace Officers’ Annuity and Benefit of Georgia Securities Laws Class Action Civil Suit</font>: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated<font style="font-weight:bold;font-style:italic;"> </font>federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and “created a false impression of DaVita’s business and operational status and future growth prospects.” The Company disputes these allegations and intends to defend this action accordingly.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Blackburn Shareholder Derivative Civil Suit</font>: On February 10, 2017, Charles Blackburn filed a derivative shareholder lawsuit in the U.S. District Court for the District of Delaware against the Company, as nominal defendant, the Board of Directors and certain executives. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in the Company’s 2016 proxy statement in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. The Company disputes these allegations and intends to defend this action accordingly.</p> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Proceedings</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters. In that regard, the Company had a pending lawsuit in the U.S. Court of Federal Claims against the federal government which was originally filed in May 2011. The lawsuit related to the U.S. Department of Veterans Affairs (VA) underpayment of dialysis services the Company provided from 2005 through 2011 to veterans pursuant to VA regulations. In January 2017, the Company reached a resolution of its claims with the government for $538,000, which the Company expects to recognize in its first quarter 2017 financial statements.</p> <p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*  *  *</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than as described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 17, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business or reputation. </p></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets and goodwill, valuation adjustments, accounting for income taxes, quarterly, annual and long-term variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements. </p></div>
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	336513000
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1365000
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2016Q4	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	11
CY2016Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	75877000
CY2016Q4	dva	Number Of Entities That Third Parties Held Non Controlling Equity Interests NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests	490
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	879874000
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	269732000
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	723114000
CY2016	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	203835000
CY2015	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	214062000
CY2014	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	214496000
CY2016	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2015	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2014	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	879874000
CY2015	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	269732000
CY2014	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	723114000
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1070000
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2190000
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2432000
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2523000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1715000
CY2016	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-12088000
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	21470000
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	131833000
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	105216000
CY2015Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	82679000
CY2016Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	2894000
CY2015Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	2427000
CY2016Q4	us-gaap	Land Land	59013000
CY2015Q4	us-gaap	Land Land	42080000
CY2016Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	491301000
CY2015Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	437283000
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2598471000
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2289425000
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2378303000
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2080446000
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	480439000
CY2016Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	7420000
CY2015Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	8969000
CY2016Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	7420000
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	103679000
CY2015Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	8969000
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	103679000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6007527000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5185747000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2832160000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2397007000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	545734000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	475484000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	428309000
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	12990000
CY2015	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	9723000
CY2014	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	7888000
CY2016Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	1568161000
CY2015Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	1575865000
CY2016Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	190761000
CY2015Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	170883000
CY2016Q4	dva	Provider Network And Practice Management Tools Gross ProviderNetworkAndPracticeManagementToolsGross	187318000
CY2015Q4	dva	Provider Network And Practice Management Tools Gross ProviderNetworkAndPracticeManagementToolsGross	183724000
CY2016Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	512505000
CY2015Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	510521000
CY2016Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1546000
CY2015Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9310000
CY2016Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	583000
CY2015Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	408000
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2468498000
CY2015Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2458017000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	940731000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	770691000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	174518000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	166537000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	167956000
CY2016	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-923000
CY2015	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-1613000
CY2014	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	-1798000
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0
CY2016Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	8485000
CY2015Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	6936000
CY2016	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	0
CY2015	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	3997000
CY2014	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	5330000
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	14993000
CY2016Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	306827000
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	107050000
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	413877000
CY2015Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	406884000
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	90322000
CY2015Q4	us-gaap	Marketable Securities MarketableSecurities	497206000
CY2016Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	306827000
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	3371000
CY2015Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	406884000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	192834000
CY2015Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	89122000
CY2015	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	377000
CY2014Q4	us-gaap	Goodwill Goodwill	9415295000
CY2015	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	97093000
CY2015	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	8781000
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	89122000
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	3701000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	2589000
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	14971000
CY2015	us-gaap	Proceeds From Sale Of Available For Sale Securities Equity ProceedsFromSaleOfAvailableForSaleSecuritiesEquity	1295000
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	690000
CY2015	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	618000
CY2016	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	423000
CY2016	dva	Income Loss From Continuing Operations Including Noncontrolling Interest Before Income Taxes IncomeLossFromContinuingOperationsIncludingNoncontrollingInterestBeforeIncomeTaxes	1488895000
CY2015	dva	Income Loss From Continuing Operations Including Noncontrolling Interest Before Income Taxes IncomeLossFromContinuingOperationsIncludingNoncontrollingInterestBeforeIncomeTaxes	723136000
CY2014	dva	Income Loss From Continuing Operations Including Noncontrolling Interest Before Income Taxes IncomeLossFromContinuingOperationsIncludingNoncontrollingInterestBeforeIncomeTaxes	1309673000
CY2015	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-16294000
CY2016	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	447828000
CY2016	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	44759000
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	281415000
CY2016	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-8816000
CY2016Q4	us-gaap	Goodwill Gross GoodwillGross	9883410000
CY2016Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	476093000
CY2014	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1000000
CY2016Q4	dva	Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.03
CY2016Q4	dva	Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.0100
CY2016Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	277482000
CY2015Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	153104000
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7217000
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	29050000
CY2016Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	80437000
CY2015Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	80355000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	82234000
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81585000
CY2016Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	36645000
CY2015Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	53687000
CY2016Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	27759000
CY2015Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	29291000
CY2016Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	345073000
CY2015Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	255051000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1144544000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	764998000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1341208000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	344351000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-41862000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-31535000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.012
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2016	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	-0.098
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.067
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.117
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.006
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.026
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.006
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.015
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.035
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.113
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.040
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.306
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.409
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.341
CY2016Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	381523000
CY2016Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0
CY2016Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	19283000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	318596000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	130456000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	147487000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	615822000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56016000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	559806000
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1025488000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	230870000
CY2016Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	95936000
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	16640000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1368934000
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	809128000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1795000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	299682000
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	460093000
CY2016Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	263995000
CY2015Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	261960000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	563204000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	514287000
CY2016	dva	Increase Decrease In Realizability Of Losses IncreaseDecreaseInRealizabilityOfLosses	8339000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	39011000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	9714000
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	23382000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	31877000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6131000
CY2015	dva	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2999000
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1996000
CY2016	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0443
CY2016Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0452
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	394279000
CY2015	us-gaap	Interest Expense Debt InterestExpenseDebt	389755000
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	385750000
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	20103000
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18625000
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24544000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	473302000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	442959000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	401242000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	354559000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	310704000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1244309000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3227075000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	37758000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	34442000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	35292000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	35575000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	31133000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	232191000
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	406391000
CY2016	us-gaap	Unrecorded Unconditional Purchase Obligation Description UnrecordedUnconditionalPurchaseObligationDescription	Certain consolidated joint ventures are originally contractually scheduled to dissolve after terms ranging from 10 to 50 years.
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	7337266
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	106709000
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	64.90
CY2016Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3026721
CY2016Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	56.83
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	73001000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	116933000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	151342000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	79717000
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23566000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7500000
CY2016	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	73337000
CY2015	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	130682000
CY2014	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	118970000
CY2016	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	12731000
CY2015	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	19689000
CY2014	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	20351000
CY2016Q4	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	92987000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	59016000
CY2016	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P1Y
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	28397000
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	45749000
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	59119000
CY2016	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2015	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2014	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	0
CY2016	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	16649090
CY2015	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	7779958
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1072377000
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	575380000
CY2016	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	64.41
CY2015	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	73.96
CY2016Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	1240748000
CY2015Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	259252000
CY2016Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	677104000
CY2016	dva	Charter Documents And Delaware Law Description CharterDocumentsAndDelawareLawDescription	The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law which, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company.
CY2016	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-13105000
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-55826000
CY2014	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-5002000
CY2016	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	866769000
CY2015	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	213906000
CY2014	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	718112000
CY2014	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	136000
CY2016	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P7Y
CY2015	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P8Y
CY2014	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2016Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	173718000
CY2015Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	73733000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	215872000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	170477000
CY2014Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	175247000
CY2016	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14875592000
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	14342138000
CY2016	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	884284000
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	280124000
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	4.39
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	1.32
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	4.32
CY2015	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	18965000
CY2014	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	13012000
CY2015	dva	Debt Redemption And Refinancing Charges DebtRedemptionAndRefinancingCharges	48072000
CY2014	dva	Debt Redemption And Refinancing Charges DebtRedemptionAndRefinancingCharges	97548000
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	339411000
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	156075000
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	238615000
CY2016	us-gaap	Interest Paid InterestPaid	406987000
CY2015	us-gaap	Interest Paid InterestPaid	405120000
CY2014	us-gaap	Interest Paid InterestPaid	351967000
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	28127000
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	74035000
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	72389000
CY2016Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3717651000
CY2016Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3581136000
CY2015Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3533589000
CY2015Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3525665000
CY2015Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3434618000
CY2015Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	3287965000
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	329070000
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	364889000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	244935000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	509368000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	480548000
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-64156000
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	1.30
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	34135000
CY2016	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	1511000
CY2016	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	4132000
CY2016	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	21537000
CY2016Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	9977000
CY2016Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	747574000
CY2016Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	425034000
CY2016Q4	dva	Number Of Customers Accounting For Approximately11 Of Consolidated Net Revenues NumberOfCustomersAccountingForApproximately11OfConsolidatedNetRevenues	1
CY2016Q4	dva	Number Of Customers Accounting For More Than10 Of Consolidated Accounts Receivable NumberOfCustomersAccountingForMoreThan10OfConsolidatedAccountsReceivable	0
CY2015Q4	dva	Number Of Customers Accounting For More Than10 Of Consolidated Accounts Receivable NumberOfCustomersAccountingForMoreThan10OfConsolidatedAccountsReceivable	0
CY2016	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	44561000
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	229391000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	264981000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	146307000
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	408371000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	330539000
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-162081000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	53382000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	97434000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-6000000
CY2014	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	596077000
CY2014	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	373096000
CY2014	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-7989000
CY2014	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-156990000
CY2016	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	563856000
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	64725000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-110617000
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.80
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.80
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.76
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.47
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.00
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2015	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	456452000
CY2014	dva	Debt Expense Including Debt Refinancing Charges DebtExpenseIncludingDebtRefinancingCharges	507842000
CY2016Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1149739000
CY2016Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	650578000
CY2016Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10221813000
CY2015Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1279936000
CY2015Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	241050000
CY2015Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10167499000
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	930362000
CY2016	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	64725000
CY2016	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-126558000
CY2016	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-124442000
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1227539000
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1129790000
CY2015	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	97032000
CY2015	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	619698000
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-758668000

Files In Submission

Name	View Source	Status
0001564590-17-002409-index-headers.html	Edgar Link	pending
0001564590-17-002409-index.html	Edgar Link	pending
0001564590-17-002409.txt	Edgar Link	pending
0001564590-17-002409-xbrl.zip	Edgar Link	pending
dva-10k_20161231.htm	Edgar Link	pending
dva-20161231.xml	Edgar Link	completed
dva-20161231.xsd	Edgar Link	pending
dva-20161231_cal.xml	Edgar Link	unprocessable
dva-20161231_def.xml	Edgar Link	unprocessable
dva-20161231_lab.xml	Edgar Link	unprocessable
dva-20161231_pre.xml	Edgar Link	unprocessable
dva-ex1012_1295.htm	Edgar Link	pending
dva-ex1013_1293.htm	Edgar Link	pending
dva-ex1016_1294.htm	Edgar Link	pending
dva-ex105_1731.htm	Edgar Link	pending
dva-ex106_1730.htm	Edgar Link	pending
dva-ex121_8.htm	Edgar Link	pending
dva-ex211_7.htm	Edgar Link	pending
dva-ex231_10.htm	Edgar Link	pending
dva-ex311_6.htm	Edgar Link	pending
dva-ex312_12.htm	Edgar Link	pending
dva-ex321_9.htm	Edgar Link	pending
dva-ex322_11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2017022421005470210822.jpg	Edgar Link	pending
g2017022421005470810823.jpg	Edgar Link	pending
g2017022421005606310824.jpg	Edgar Link	pending
g2017022421010459210825.jpg	Edgar Link	pending
g2017022421010563910826.jpg	Edgar Link	pending
g2017022421010564310827.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2015 Q4 Form 10-K Financial Statement

#000156459017002409 Filed on February 24, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2015 Q4 Form 10-K Financial Statement

#000156459017002409 Filed on February 24, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva